Simultaneous Immunization with Multivalent Norovirus VLPs Induces Better Protective Immune Responses to Norovirus Than Sequential Immunization.
Animals
Antibodies, Blocking
/ blood
Antibodies, Viral
/ blood
Antigens, Viral
/ immunology
Caliciviridae Infections
/ immunology
Capsid Proteins
/ immunology
Cross Reactions
Female
Genotype
Immunization
/ methods
Immunization Schedule
Mice
Mice, Inbred BALB C
Norovirus
/ genetics
Vaccines, Combined
/ administration & dosage
Vaccines, Virus-Like Particle
/ administration & dosage
Viral Vaccines
/ administration & dosage
VLP
blocking antibodies
cross-reactivity
genotype
norovirus
original antigenic sin (OAS)
pre-existing immunity
vaccine
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
02 11 2019
02 11 2019
Historique:
received:
23
09
2019
revised:
25
10
2019
accepted:
31
10
2019
entrez:
6
11
2019
pubmed:
7
11
2019
medline:
17
9
2020
Statut:
epublish
Résumé
Human noroviruses (NoVs) are a genetically diverse, constantly evolving group of viruses. Here, we studied the effect of NoV pre-existing immunity on the success of NoV vaccinations with genetically close and distant genotypes. A sequential immunization as an alternative approach to multivalent NoV virus-like particles (VLPs) vaccine was investigated. Mice were immunized with NoV GI.3, GII.4-1999, GII.17, and GII.4 Sydney as monovalent VLPs or as a single tetravalent mixture combined with rotavirus VP6-protein. Sequentially immunized mice were primed with a trivalent vaccine candidate (GI.3 + GII.4-1999 + VP6) and boosted, first with GII.17 and then with GII.4 Sydney VLPs. NoV serum antibodies were analyzed. Similar NoV genotype-specific immune responses were induced with the monovalent and multivalent mixture immunizations, and no immunological interference was observed. Multivalent immunization with simultaneous mix was found to be superior to sequential immunization, as sequential boost induced strong blocking antibody response against the distant genotype (GII.17), but not against GII.4 Sydney, closely related to GII.4-1999, contained in the priming vaccine. Genetically close antigens may interfere with the immune response generation and thereby immune responses may be differently formed depending on the degree of NoV VLP genotype identity.
Identifiants
pubmed: 31684058
pii: v11111018
doi: 10.3390/v11111018
pmc: PMC6893631
pii:
doi:
Substances chimiques
Antibodies, Blocking
0
Antibodies, Viral
0
Antigens, Viral
0
Capsid Proteins
0
VP6 protein, Rotavirus
0
Vaccines, Combined
0
Vaccines, Virus-Like Particle
0
Viral Vaccines
0
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
J Infect Dis. 2014 Dec 1;210(11):1755-62
pubmed: 24970849
Microbes Infect. 2014 Jun;16(6):472-80
pubmed: 24631874
Hum Vaccin Immunother. 2014;10(7):2039-47
pubmed: 25424814
Methods Mol Biol. 2016;1403:259-68
pubmed: 27076135
BMC Infect Dis. 2019 Feb 19;19(1):177
pubmed: 30782126
Epidemiol Infect. 2012 Feb;140(2):268-75
pubmed: 21489338
J Clin Microbiol. 2017 Dec;55(12):3366-3373
pubmed: 28904188
PLoS Pathog. 2012;8(7):e1002802
pubmed: 22829765
PLoS Med. 2016 Apr 26;13(4):e1001999
pubmed: 27115709
Pharmaceutics. 2019 May 11;11(5):null
pubmed: 31083495
J Infect Dis. 2014 Dec 1;210(11):1763-71
pubmed: 24951828
J Clin Microbiol. 2014 Jan;52(1):147-55
pubmed: 24172151
J Immunol Res. 2016;2016:9171632
pubmed: 27689099
Clin Ther. 2017 Aug;39(8):1537-1549
pubmed: 28756066
J Infect Dis. 2018 Jan 30;217(4):597-607
pubmed: 29140444
Euro Surveill. 2015 Jul 02;20(26):null
pubmed: 26159308
J Virol. 2002 Dec;76(23):12335-43
pubmed: 12414974
Vaccine. 2011 Oct 19;29(45):8126-33
pubmed: 21854823
J Gen Virol. 2019 Oct;100(10):1393-1406
pubmed: 31483239
J Clin Microbiol. 2010 Jan;48(1):168-77
pubmed: 19864482
Vaccine. 2018 Jan 25;36(4):484-490
pubmed: 29246474
Clin Infect Dis. 2014 Feb;58(4):483-91
pubmed: 24300042
Eur J Pediatr. 2015 Dec;174(12):1679-83
pubmed: 26152345
J Infect Dis. 2010 Sep 1;202 Suppl:S101-7
pubmed: 20684688
J Virol. 2012 Jan;86(2):873-83
pubmed: 22090098
Mol Immunol. 2016 Oct;78:27-37
pubmed: 27573255
Proc Natl Acad Sci U S A. 1999 Nov 23;96(24):14001-6
pubmed: 10570188
J Gen Virol. 2006 Apr;87(Pt 4):909-19
pubmed: 16528040
PLoS One. 2013 Jul 26;8(7):e70409
pubmed: 23922988
J Immunol. 2009 Sep 1;183(5):3294-301
pubmed: 19648276
J Virol. 2013 Jun;87(11):6270-82
pubmed: 23536665
Viral Immunol. 2013 Apr;26(2):167-70
pubmed: 23438469
JCI Insight. 2018 Jul 12;3(13):
pubmed: 29997294
J Med Virol. 2015 Oct;87(10):1656-61
pubmed: 25946711
Viruses. 2019 Jan 22;11(2):
pubmed: 30678195
Vaccine. 2018 Aug 28;36(36):5435-5441
pubmed: 28668568
J Infect Dis. 2017 Apr 1;215(7):1059-1099
pubmed: 28180277
J Infect Dis. 2009 Sep 1;200(5):802-12
pubmed: 19627248
Clin Exp Immunol. 2017 Sep;189(3):331-341
pubmed: 28407442
PLoS Pathog. 2016 Apr 26;12(4):e1005334
pubmed: 27115358
J Virol. 1992 Nov;66(11):6527-32
pubmed: 1328679
Trends Microbiol. 2005 Jun;13(6):285-93
pubmed: 15936661
Arch Virol. 2010 Nov;155(11):1855-8
pubmed: 20721592
J Med Virol. 2011 Mar;83(3):525-31
pubmed: 21264875
Lancet Infect Dis. 2019 Jul;19(7):717-727
pubmed: 31178289
Microbes Infect. 2016 Apr;18(4):263-9
pubmed: 26724451
Cell Mol Gastroenterol Hepatol. 2019;7(3):686-688.e5
pubmed: 30543870
Clin Vaccine Immunol. 2015 Jun;22(6):656-63
pubmed: 25903355
J Infect Dis. 2010 Oct 15;202(8):1212-8
pubmed: 20815703
Vaccine. 2006 Jun 12;24(24):5220-34
pubmed: 16650512
Viral Immunol. 2018 Nov 15;:null
pubmed: 30431404
Sci Rep. 2019 Mar 1;9(1):3199
pubmed: 30824789